Drug News

Added 14 days ago Drug news

Alnylam announces new and enhanced framework for value-based agreements to accelerate patient and provider access to Givlaari.

Alnylam Pharmaceuticals, Inc. announces a new and enhanced framework for value-based agreements (VBAs) designed to help patients with acute hepatic...

Added 2 hours ago Drug news

Phase III studies of DAXI in glabellar lines published in JAAD.- Revance Therapeutics

Revance Therapeutics announced the publication of the pooled data from two multicenter, randomized, double-blind, placebo-controlled Phase III studies (SAKURA 1...

Added 2 hours ago Drug news

AURORA phase III trial of Luveniq meets primary endpoint in lupus nephritis.- Aurinia Pharma

Aurinia Pharmaceuticals Inc. announced positive top-line results announced positive efficacy and safety results from its pivotal AURORA Phase III trial...

Added 2 hours ago Drug news

FDA approves Cobas vivoDx MRSA diagnostic test for detection of bacterial infection.- Roche

The FDA has authorized marketing of the Cobas vivoDx MRSA diagnostic test, from Roche, based on bacterial viability and novel...

Added 2 hours ago Drug news

Positive phase III ACHIEVE I trial results for ubrogepant published in NEJM.- Allergan

Allergan plc announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase III clinical trial evaluating the efficacy, safety...

Added 2 hours ago Drug news

Positive data in pivotal trial of hematopoietic stem cell transplant- associated thrombotic microangiopathy patients treated with narsoplimab.-Omeros Corpn.

Omeros Corporation announced positive data from its pivotal clinical trial of the company’s novel investigational complement inhibitor narsoplimab in the...

Added 2 hours ago Drug news

Phase III HARMONY study of Nuplazid meets primary endpoint in dementia-related psychosis.- Acadia Pharma

Acadia Pharmaceuticals presented positive top-line results from its Phase III HARMONY study of Nuplazid (pimavanserin) for the treatment of dementia-related...

Added 2 hours ago Drug news

Phase III MOUNTAIN Study of SAGE 217 fails to meet endpoint in major depressive disorder.- Sage Therapeutics

Sage Therapeutics reported topline results from the pivotal Phase III MOUNTAIN Study evaluating the effect of SAGE 217 (zuranolone) on...

Added 2 hours ago Drug news

GSK 3684934 filed with FDA for HIV-1 infection.- ViiV Healthcare

ViiV Healthcare completed submission of a New Drug Application (NDA) to the FDA seeking approval of GSK 3684934 (fostemsavir) an...

Added 1 day ago Drug news

FDA approves Tecentriq + chemotherapy (Abraxane and carboplatin) to treat metastatic non-squamous non-small cell lung cancer.- Genentech/Roche

Genentech, a member of the Roche Group announced that the FDA approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel...

Search all news articles